The opening of the 21st century has been heralded as a turning point in biomedical research. The complete sequence and a dense map of the human genome, coupled with advanced genomics technologies holds the promise of dramatically accelerating the understanding of human disease, which in turn is expected to accelerate the pace of discovery of new therapeutics. Similarly, recent advances in synthetic organic chemistry have the potential to greatly improve chemical screening and compound optimization. In principle, these technical and conceptual advances have the potential to transform drug discovery. In practice, however, they have not yet done so. While emerging genomic and chemical technologies are available in isolation, they have not been creatively integrated into the drug discovery process. A key reason has been the lack of a concerted, interdisciplinary effort to merge the disciplines of genetics and chemistry into a new conceptual framework. We propose here an ambitious plan to create a new approach to drug discovery involving four components. Component A (U54 Leadership) which includes the IRC Steering Committee. Component B (Discovery Pipeline). This component aims to develop a drug discovery pipeline based on the paradigm of phenotypic screening. This includes developing i) systematic high-throughput screening of phenotypic assays for cellular states based on gene-expression and imaging;ii) expanded libraries of DOS compounds to facilitate high-throughput screening, target identification and medicinal chemistry optimization;and iii)genomics-based approaches to predictive toxicology. Component C (Target ID).This component aims to develop systematic approaches to identifying the protein target of a small molecule based on i) techniques for affinity capture and proteomic analysis;ii) novel approaches using RNA inhibition (RNAi);and iii) novel computational approaches to recognize distinctive cellular signatures. Component D (Driving Medical Projects). To drive its development and test its utility, the new paradigm must be applied to specific biomedical problems. This component will undertake six demonstration projects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
6UL1DE019585-03
Application #
7653726
Study Section
Special Emphasis Panel (ZRR1-SRC (99))
Program Officer
Riddle, Melissa
Project Start
2007-09-20
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$343,747
Indirect Cost
Name
Broad Institute, Inc.
Department
Type
DUNS #
623544785
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Yu, Channing; Mannan, Aristotle M; Yvone, Griselda Metta et al. (2016) High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol 34:419-23
Chao, Ariana M; Grilo, Carlos M; Sinha, Rajita (2016) Food cravings, binge eating, and eating disorder psychopathology: Exploring the moderating roles of gender and race. Eat Behav 21:41-7
Frumm, Stacey M; Fan, Zi Peng; Ross, Kenneth N et al. (2013) Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol 20:713-25
Mulrooney, Carol A; Lahr, David L; Quintin, Michael J et al. (2013) An informatic pipeline for managing high-throughput screening experiments and analyzing data from stereochemically diverse libraries. J Comput Aided Mol Des 27:455-68
Taipale, Mikko; Krykbaeva, Irina; Whitesell, Luke et al. (2013) Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol 31:630-7
Gerard, Baudouin; Lee 4th, Maurice D; Dandapani, Sivaraman et al. (2013) Synthesis of stereochemically and skeletally diverse fused ring systems from functionalized C-glycosides. J Org Chem 78:5160-71
Lowe, Jason T; Lee 4th, Maurice D; Akella, Lakshmi B et al. (2012) Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. J Org Chem 77:7187-211
Luo, Tuoping; Masson, Kristina; Jaffe, Jacob D et al. (2012) STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A 109:2860-5
Wen, Qiang; Goldenson, Benjamin; Silver, Serena J et al. (2012) Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 150:575-89
Fitzgerald, Mark E; Mulrooney, Carol A; Duvall, Jeremy R et al. (2012) Build/couple/pair strategy for the synthesis of stereochemically diverse macrolactams via head-to-tail cyclization. ACS Comb Sci 14:89-96

Showing the most recent 10 out of 12 publications